The mechanisms underlying sorafenib resistance are multifaceted, involving the dysregulation of several critical signaling pathways, notably the PI3K/AKT and JAK/STAT pathways, which are crucial for tumor cell proliferation, apoptosis, and metastasis (Zhu et al., 2017; Zhang et al., 2018). This evidence concerns the gene AKT1 and neoplasm.